OncoCyte Corp (OCX)
2.75
+0.08
(+3.00%)
USD |
NASDAQ |
Nov 22, 13:42
OncoCyte Enterprise Value: 41.59M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 41.59M |
| November 20, 2024 | 42.93M |
| November 19, 2024 | 39.57M |
| November 18, 2024 | 40.91M |
| November 15, 2024 | 40.58M |
| November 14, 2024 | 43.78M |
| November 13, 2024 | 46.13M |
| November 12, 2024 | 47.14M |
| November 11, 2024 | 45.46M |
| November 08, 2024 | 44.79M |
| November 07, 2024 | 44.45M |
| November 06, 2024 | 44.45M |
| November 05, 2024 | 45.80M |
| November 04, 2024 | 45.46M |
| November 01, 2024 | 47.14M |
| October 31, 2024 | 47.65M |
| October 30, 2024 | 47.48M |
| October 29, 2024 | 48.83M |
| October 28, 2024 | 48.83M |
| October 25, 2024 | 47.82M |
| October 24, 2024 | 47.98M |
| October 23, 2024 | 49.67M |
| October 22, 2024 | 48.49M |
| October 21, 2024 | 49.16M |
| October 18, 2024 | 49.33M |
| Date | Value |
|---|---|
| October 17, 2024 | 49.16M |
| October 16, 2024 | 48.99M |
| October 15, 2024 | 49.16M |
| October 14, 2024 | 49.16M |
| October 11, 2024 | 47.98M |
| October 10, 2024 | 48.83M |
| October 09, 2024 | 48.32M |
| October 08, 2024 | 47.82M |
| October 07, 2024 | 47.31M |
| October 04, 2024 | 45.29M |
| October 03, 2024 | 36.49M |
| October 02, 2024 | 37.43M |
| October 01, 2024 | 36.63M |
| September 30, 2024 | 34.75M |
| September 27, 2024 | 29.26M |
| September 26, 2024 | 30.47M |
| September 25, 2024 | 29.93M |
| September 24, 2024 | 30.87M |
| September 23, 2024 | 32.87M |
| September 20, 2024 | 35.41M |
| September 19, 2024 | 30.87M |
| September 18, 2024 | 30.20M |
| September 17, 2024 | 32.34M |
| September 16, 2024 | 32.87M |
| September 13, 2024 | 31.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.336M
Minimum
Dec 20 2022
565.53M
Maximum
Feb 16 2021
119.31M
Average
76.41M
Median
Jul 22 2020
Enterprise Value Benchmarks
| Fonar Corp | 41.17M |
| XWELL Inc | 0.1013M |
| ProPhase Labs Inc | 35.22M |
| Applied DNA Sciences Inc | -8.969M |
| Veracyte Inc | 2.744B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.49M |
| Revenue (Quarterly) | 0.115M |
| Total Expenses (Quarterly) | 6.49M |
| EPS Diluted (Quarterly) | -0.98 |
| Gross Profit Margin (Quarterly) | 43.48% |
| Profit Margin (Quarterly) | -11.73K% |
| Earnings Yield | -165.1% |
| Normalized Earnings Yield | -84.88 |